GlassScriptPhysician profile
Marc O Merbaum
NPI 1245204338
$822.88
in general payments reported to CMS, 2019-2025
16 companies · $18.81 in 2025
The $18.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.21 · 2020: $37.70 · 2021: $112 · 2022: $204 · 2023: $207 · 2024: $147 · 2025: $18.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222.15 | 2022-2025 | |
| Astellas Pharma US INC | $91.80 | 2019-2023 | Veozah |
| Lilly USA, LLC | $89.48 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $87.22 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $55.64 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $39.30 | 2023-2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $36.47 | 2021-2022 | |
| Abbott Laboratories | $33.24 | 2020-2022 | |
| Amgen INC. | $32.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $26.65 | 2022 | |
| Novo Nordisk INC | $26.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.18 | 2024 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $16.27 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.89 | 2022 | |
| Amarin Pharma, INC. | $15.76 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $14.31 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Merbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.